Showing 1821-1830 of 5771 results for "".
- Glaukos Announces Settlement of Patent Litigation with Ivantishttps://modernod.com/news/glaukos-announces-settlement-of-patent-litigation-with-ivantis/2480278/Glaukos announced it has entered into a settlement agreement with Ivantis agreeing to terminate the patent infringement lawsuit Glaukos initiated on April 14, 2018 in the U.S. District Court for the Central District of California, Southern Division, concerning Ivantis’ Hydrus Micr
- Aurion Biotech Announces Strategic Investments in Manufacturinghttps://modernod.com/news/aurion-biotech-announces-strategic-investments-in-manufacturing/2480275/Aurion Biotech announced it has appointed Tim Largen as vice president of manufacturing. Mr. Largen is based in Seattle and will lead strategy and development of Aurion Biotech’s global cell manufacturing capabilities. His role will include managing Aurion Biotech’s internal team and
- GenSight Biologics Announces Publication Analyzing ND4-LHON Before Lumevoq Treatment in Phase 3 Trialshttps://modernod.com/news/gensight-biologics-announces-publication-analyzing-nd4-lhon-before-lumevoq-treatment-in-phase-3-trials/2479578/GenSight Biologics announced that the Journal of Neuro-Ophthalmology has published a paper on a cross-sectional analysis of the baseline (pre-treatment) characteristics of the ND4-LHON subjects enrolled in the RESCUE and REVERSE phase 3 trials of Lumevoq. The paper,* p
- Gemini Therapeutics Announces Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021https://modernod.com/news/gemini-therapeutics-announces-data-from-its-ongoing-phase-2a-study-of-gem103-at-euretina-2021/2479579/Gemini Therapeutics announced that Raj Maturi, MD, Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini’s previously released initial results from its ongoing phase 2a study at EURETINA 2021
- MeiraGTx Announces Data at EURETINA 2021 Demonstrating Reversal of Disease Progression Following Treatment With AAV5-RPGR in XLRPhttps://modernod.com/news/meiragtx-announces-data-at-euretina-2021-demonstrating-reversal-of-disease-progression-following-treatment-with-aav5-rpgr-in-xlrp/2479499/MeiraGTx Holdings announced new data from subjects treated in the phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal fun
- Samsung Bioepis Announces Results From Post-Hoc Analysis of Phase 3 Study of Ranibizumab Biosimilar Byoovizhttps://modernod.com/news/samsung-bioepis-announces-results-from-post-hoc-analysis-of-phase-3-study-of-ranibizumab-biosimilar-byooviz/2479497/Samsung Bioepis announced results from a post-hoc and subgroup analysis of phase 3 clinical study of Byooviz (ranibizumab biosimilar) identifying the baseline factors associated with visual acuity and anatomical outcomes at both primary endpoints through week 52. The study results will be present
- ProQR Announces Axiomer RNA Editing Licensing and Research Collaboration with Lillyhttps://modernod.com/news/proqr-announces-axiomer-rna-editing-licensing-and-research-collaboration-with-lilly/2479498/ProQR Therapeutics, the developer of RNA therapies for the treatment of genetic eye diseases, announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in
- AxeroVision Announces Phase 2 Results for Dry Eye Disease Creamhttps://modernod.com/news/axerovision-announces-phase-2-results-for-axr-270-for-treatment-of-dry-eye-disease-associated-with-mgd/2479478/AxeroVision announced positive results from a phase 2 investigational treatment of AXR-270, the company’s novel, proprietary, once-daily glucocorticoid cream, in patients with signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). I
- Regeneron Announces Topline Phase 2 Data of High-Dose Aflibercept in Wet AMDhttps://modernod.com/news/regeneron-announces-topline-phase-2-data-of-high-dose-aflibercept-in-wet-amd/2479468/Regeneron Pharmaceuticals announced that an ongoing phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of Eylea (aflibercept) injection in patients
- Sight Sciences Announces Publication of 2-Year Outcomes of Standalone Use of the OMNI Surgical Systemhttps://modernod.com/news/sight-sciences-announces-publication-of-two-year-outcomes-of-standalone-use-of-the-omni-surgical-system-in-mild-to-moderate-open-angle-glaucoma/2479466/Sight Sciences announced publication in